Peak Bio and Akari Therapeutics Report Merger Agreement to Form an Expanded Pipeline of Novel Antibody Drug Conjugate (ADC)
Shots:
- Peak Bio & Akari have entered into a definitive agreement to merge as equals. The merged entity, Akari Therapeutics, Plc., will develop cancer solutions with the combination of chemotherapy & immunotherapy strategies
- The merged pipeline will include Peak’s ADC toolkit with novel payload & linker technologies, a pre-clinical TROP-2 targeting ADC & PHP-303 (P-II for AATD) as well as Akari's nomacopan (P-III for pediatric HSCT-TMA) & PASylated-nomacopan (final stages of pre-clinical development for GA)
- As per the agreement, both Akari & Peak stockholders will hold an equity ownership of ~50% each in the combined company on a fully-diluted basis. The closing of the transaction is expected in Q2’24
Ref: Peak Bio | Image: Peak Bio
Related News:- Innovent Biologics Signs an Expanded Agreement with Synaffix for the Development of Antibody Drug Conjugates (ADCs)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
